OP2101 - OrchestratePharma initiates phase 1 bioavailability study with IVRS

OrchestratePharma is pleased to announce the initiation of its phase 1 bioavailability study for OP2101, conducted in collaboration with IVRS (Integrated Voice Response System).

This study represents a significant milestone in the development of our lead candidate — a novel topical formulation of fexofenadine designed for the treatment of atopic dermatitis (eczema).

The phase 1 study will evaluate the pharmacokinetic profile and bioavailability of OP2101 in healthy volunteers, providing critical data to support further clinical development.

OrchestratePharma's drug repurposing approach (DRPx) allows us to leverage fexofenadine's well-established safety profile while exploring its potential in new therapeutic areas, significantly reducing development timelines and costs compared to traditional drug development.